Kmt2c单倍剂量不足小鼠的转录组失调与自闭症样行为可被LSD1抑制剂逆转
研究构建Kmt2c杂合移码突变小鼠作为自闭症谱系障碍(ASD)模型,发现其表现出社交、灵活性和工作记忆受损等自闭症样行为。转录组分析显示ASD风险基因在上调差异表达基因(DEG)中富集,而KMT2C结合峰与下调基因共定位;单细胞测序揭示放射状胶质细胞和未成熟神经元中ASD相关转录组变化。LSD1抑制剂vafidemstat可改善社交障碍但不改善工作记忆,并逆转大部分DEG表达方向。
要点
- Kmt2c+/fs小鼠表现出社交、灵活性和工作记忆受损的自闭症样行为。
- ASD风险基因富集于上调DEG,KMT2C结合峰与下调基因共定位。
- vafidemstat改善社交障碍但不改善工作记忆,并逆转多数DEG表达方向。
核心结论
- Kmt2c单倍剂量不足通过间接转录组失调导致自闭症样行为,LSD1抑制剂vafidemstat可部分逆转行为与分子异常。
研究设计与样本
- 研究构建并分析Kmt2c杂合移码突变(Kmt2c+/fs)小鼠作为ASD疾病模型,进行行为学分析、全脑转录组分析、新生小鼠脑单细胞RNA测序及药物干预实验。
主要发现
- 突变小鼠表现出社交、灵活性和工作记忆受损等自闭症样行为。
- 成年突变小鼠全脑转录组中ASD风险基因特异富集于上调DEG,KMT2C ChIP-seq峰与下调基因显著共定位。
- 新生小鼠脑单细胞RNA测序显示放射状胶质细胞和未成熟神经元中ASD相关转录组变化显著,无上调或下调偏倚,细胞组成无显著总体改变。
- vafidemstat改善成年Kmt2c+/fs小鼠社交障碍但不改善工作记忆。
- vafidemstat使94.3%显著上调DEG和82.5%显著下调DEG的表达方向正常化(P < 2.2 × 10-16,二项检验)。
关键数值与推荐
- vafidemstat逆转显著上调DEG的比例为94.3%,逆转显著下调DEG的比例为82.5%(P < 2.2 × 10-16,二项检验)。
临床怎么用
- Kmt2c+/fs小鼠可作为高病因效度和表观效度的ASD模型用于机制与治疗研究。
- LSD1抑制剂vafidemstat可能对KMT2C单倍剂量不足相关ASD社交障碍具有治疗潜力,但对工作记忆损害无效。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent studies have consistently demonstrated that the regulation of chromatin and gene transcription plays a pivotal role in the pathogenesis of neurodevelopmental disorders. Among many genes involved in these pathways, KMT2C, encoding one of the six known histone H3 lysine 4 (H3K4) methyltransferases in humans and rodents, was identified as a gene whose heterozygous loss-of-function variants are causally associated with autism spectrum disorder (ASD) and the Kleefstra syndrome phenotypic spectrum. However, little is known about how KMT2C haploinsufficiency causes neurodevelopmental deficits and how these conditions can be treated. To address this, we developed and analyzed genetically engineered mice with a heterozygous frameshift mutation of Kmt2c (Kmt2c+/fs mice) as a disease model with high etiological validity. In a series of behavioral analyses, the mutant mice exhibit autistic-like behaviors such as impairments in sociality, flexibility, and working memory, demonstrating their face validity as an ASD model. To investigate the molecular basis of the observed abnormalities, we performed a transcriptomic analysis of their bulk adult brains and found that ASD risk genes were specifically enriched in the upregulated differentially expressed genes (DEGs), whereas KMT2C peaks detected by ChIP-seq were significantly co-localized with the downregulated genes, suggesting an important role of putative indirect effects of Kmt2c haploinsufficiency. We further performed single-cell RNA sequencing of newborn mouse brains to obtain cell type-resolved insights at an earlier stage. By integrating findings from ASD exome sequencing, genome-wide association, and postmortem brain studies to characterize DEGs in each cell cluster, we found strong ASD-associated transcriptomic changes in radial glia and immature neurons with no obvious bias toward upregulated or downregulated DEGs. On the other hand, there was no significant gross change in the cellular composition. Lastly, we explored potential therapeutic agents and demonstrate that vafidemstat, a lysine-specific histone demethylase 1 (LSD1) inhibitor that was effective in other models of neuropsychiatric/neurodevelopmental disorders, ameliorates impairments in sociality but not working memory in adult Kmt2c+/fs mice. Intriguingly, the administration of vafidemstat was shown to alter the vast majority of DEGs in the direction to normalize the transcriptomic abnormalities in the mutant mice (94.3 and 82.5% of the significant upregulated and downregulated DEGs, respectively, P < 2.2 × 10-16, binomial test), which could be the molecular mechanism underlying the behavioral rescuing. In summary, our study expands the repertoire of ASD models with high etiological and face validity, elucidates the cell-type resolved molecular alterations due to Kmt2c haploinsufficiency, and demonstrates the efficacy of an LSD1 inhibitor that might be generalizable to multiple categories of psychiatric disorders along with a better understanding of its presumed mechanisms of action.
引用
- Nakamura T, Yoshihara T, Tanegashima C, et al. Transcriptomic dysregulation and autistic-like behaviors in Kmt2c haploinsufficient mice rescued by an LSD1 inhibitor. Mol Psychiatry. 2024. PMID: 38528071. doi:10.1038/s41380-024-02479-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。